Australia's Actinogen Medical enrols final patient into XanADu trial.
M2 EQUITYBITES-November 27, 2018-Australia's Actinogen Medical enrols final patient into XanADu trial
(C)2018 M2 COMMUNICATIONS http://www.m2.com
Australia-based Actinogen Medical has enrolled the final patient in XanADu, a phase two clinical trial to assess Xanamem intended for the treatment of patients with mild Alzheimer's disease, it was reported yesterday.
The company enrolled a total of 186 patients in the study and the increased enrolment numbers followed high engagement from study sites and research teams participating in this global Alzheimer's trial. The final patient will complete the trial in four months, following three months of treatment with Xanamem or placebo followed by a one-month observation period off-treatment. The trial data will then be collated, reviewed, and quality controlled, before being analysed. The company is on schedule to report the results during the second quarter of 2019.
XanADu is a randomised, double-blind, multi-centre clinical study comparing Xanamem to placebo in patients with mild dementia due to Alzheimer's disease. It is claimed to be the largest and most comprehensive international Alzheimer's treatment trial run by an Australian biotech company.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Nov 27, 2018|
|Previous Article:||SeraCare Life Sciences acquired by LGC.|
|Next Article:||BlueRock Therapeutics names new chief legal and administrative officer.|